Reckitt Benckiser Group stock
Price history
−5.89% over the period1 year: from 6,137.50 GBp (November 17, 2025) to 5,776.00 GBp (November 16, 2026), −5.89%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | 5,776.00 GBp |
| October 30, 2026 | 5,408.00 GBp |
| September 30, 2026 | 4,992.00 GBp |
| August 28, 2026 | 5,132.00 GBp |
| July 31, 2026 | 5,240.00 GBp |
| June 30, 2026 | 4,911.00 GBp |
| May 29, 2026 | 4,591.00 GBp |
| April 30, 2026 | 4,678.00 GBp |
| March 31, 2026 | 5,088.00 GBp |
| February 27, 2026 | 6,512.00 GBp |
| January 30, 2026 | 6,345.83 GBp |
| December 31, 2025 | 6,252.08 GBp |
| November 28, 2025 | 6,095.83 GBp |
| November 17, 2025 | 6,137.50 GBp |
At a glance
The company
Manufactures and sells health, hygiene, and nutrition products including germ protection, wellness, over-the-counter medicines, personal care, vitamins, and infant nutrition
Latest results
Quarter to June 30, 2026 · EPS £1.01 (estimate £1.48)
Next event
TickerLandia's take on Reckitt Benckiser Group
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 12 vs a median of 22 over its last 8 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 13 vs 20 (−33%) in a group of 11.
- Strong point: Profitability (76/100 in its group). Weak point: Growth (14/100).
- “Below historical valuation” (United Kingdom): No. 2 of 7.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−11.42% from the 52-week high
Analysts · 19 analysts
Average target6,270.11 GBp+8.52% vs. price
Buy 15 · Hold 4 · Sell 0 · Buy
TickerLandia Fingerprint: Reckitt Benckiser Group
Compared with similar companies: very low growth and very low financial strength.
Financials and price compared with 27 companies in the household & personal products industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage44
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 12.8 6 Forward P/E 16.1 44 Price/book 6.39 60 Price/sales 2.65 61 EV/EBITDA 12.7 50 Profitabilityhigh76
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 59.6% 69 Net margin 21.1% 91 Operating margin 22.7% 83 ROE 48.0% 80 ROA 7.9% 57 Earnings stabilitylow38
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.3% 65 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 11 Growthvery low14
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −0.58% 31 Earnings growth (year over year) −30.90% 9 Revenue growth (year over year) −8.20% 2 Financial strengthvery low19
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.74 28 Interest coverage 8.10 24 Debt/equitycounts in reverse: lower means more financial strength 1.80 20 Current ratio 0.59 2 Dividendhigh68
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 3.8% 78 Consecutive dividend years 25 years 35 Payout ratiopays out more than its earnings 101.7% 90 Market momentumstrong64
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +9.61% 78 Relative strength (6 months) +19.52% 87 1-year return −6.20% 24 Distance from 200-day average +9.68% 68 Riskhigh60
How much the price swings.
Metric Value Position in group Beta (1 year) 0.88 61 Volatility (60 days) 26.2% 46 Maximum drawdown (12 months) 31.8% 73
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Reckitt Benckiser Group is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Reckitt Benckiser Group's P/E today is 11.8, below the median of its last 8 fiscal years (21.7; between 12.8 and 41.1 from 2016 to 2025). Reckitt Benckiser Group's P/E (trailing 12 months): 13.0, −33% against the median of a group of 11 similar companies (19.6).
Compared with 11 similar companies
| Metric | Reckitt Benckiser Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 13.0 | Low | |
| Forward P/E | 16.3 | Middle | |
| Operating margin | 22.7% | High | |
| ROE | 48.0% | High | |
| Debt/equity | 1.80 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Reckitt Benckiser Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
£6.41B
Latest quarter · Q2 2026
Net income
£652M
Latest quarter · Q2 2026
Quarterly net margin
10.2%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- £36.61B
- P/E
- 13.0
- EPS
- 444.00 GBp
- Volume
- 24.29K
- Daily trading
- €95.53M
- Dividend yield
- 3.75%
- Last ex-dividend on August 6, 2026
How Reckitt Benckiser Group is changing
All resultsRevenue grew 0.3% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 102% of net income
Shares outstanding down 4.6% in 5 years
Returns
Reckitt Benckiser Group returns with dividends
£1,000 invested in Reckitt Benckiser Group 5 years ago, on November 16, 2021, would be worth £1,122 today with dividends reinvested: +12.17% in total, +2.32% per year. On price alone it would be £897 (−10.30%).
| Period | Reckitt Benckiser Group | FTSE 100 | £1,000 becomes |
|---|---|---|---|
| 1 month | +3.44% | +0.53% | £1,034 |
| 6 months | +25.69% | +7.30% | £1,257 |
| Year to date | −7.61% | +10.15% | £924 |
| 1 year | +1.79% | +13.07% | £1,018 |
| 3 years | +21.90% | +47.62% | £1,219 |
| 5 years | +12.17% | +49.31% | £1,122 |
| 10 years | +14.71% | +62.08% | £1,147 |
Over the last 6 months it has done better than 73% of the stocks in the Consumer sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment
The chart in detail
Reckitt Benckiser Group: technical analysis
Reckitt Benckiser Group shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 31.6% below its highest close since January 1, 1990 (8,445.83 GBp, June 6, 2017).
- Trend
- No clear trend
- RSI (14 sessions)
- 67
- Between 30 and 70
- vs 200-session average
- +11.18%
Active signals
Close above the high of the previous 55 sessions.
Golden cross: the 50-session average has crossed above the 200-session average.
since November 10, 2026
Support and resistance
Price areas where Reckitt Benckiser Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance6,516.52 GBp+12.78%3 touches, last on February 27, 2026
- Resistance6,300.69 GBp+9.05%3 touches, last on December 19, 2025
- Last price5,778.00 GBp
- Support5,651.00 GBp−2.20%2 touches, last on October 23, 2026
- Support5,421.00 GBp−6.18%2 touches, last on September 1, 2026
- Support5,139.00 GBp−11.06%2 touches, last on September 15, 2026
Volatility and risk
Over the last year it has moved roughly in line with the FTSE 100.
- Beta (1 year) vs FTSE 100
- 0.89
- Volatility (60 sessions, annualised)
- 25.8%
- Largest fall in the last year
- −31.77%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Reckitt Benckiser Group: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Reckitt Benckiser Group has been July: +2.93% on average, positive in 26 years out of 37. The weakest has been November: −0.86% on average, positive in 18 years out of 36.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.26% | −0.28% | 18 of 36 |
| February | +1.59% | +3.08% | 25 of 37 |
| March | −0.16% | +1.44% | 21 of 37 |
| April | +2.16% | +1.83% | 24 of 37 |
| May | +1.07% | +0.45% | 20 of 37 |
| June | −0.64% | −1.53% | 16 of 37 |
| July | +2.93% | +2.84% | 26 of 37 |
| August | −0.48% | +0.29% | 21 of 37 |
| September | +0.16% | +0.51% | 21 of 37 |
| October | +1.26% | +0.44% | 19 of 37 |
| November | −0.86% | −0.18% | 18 of 36 |
| December | +1.22% | +1.63% | 25 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Reckitt Benckiser Group and its competitors
Consumers in the United Kingdom and in markets around the world buy the health, hygiene and nutrition products sold by Reckitt Benckiser Group plc. The range runs from over-the-counter medicines such as Nurofen, Gaviscon, Strepsils and Mucinex, and intimate wellness brands Durex and KY, to germ protection under Dettol and home cleaning and disinfectants under Finish, Harpic and Lysol. The company also sells stain removal under Vanish, personal care under Clearasil and Veet, vitamins and supplements under MegaRed, Airborne, Movefree and neuriva, and infant and young children's nutrition under Enfamil and Nutramigen.
- Headquarters
- Slough, United Kingdom
- Employees
- 36,200
- Founded
- 1819
- Chief executive
- Kristoffer Licht
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Reckitt Benckiser GroupRKT | $48.42B | 22.7% | 13.0 | +25.69% |
| Henkel & Kgaa PrefHEN3 | $35.06B | 13.9% | 16.7 | +36.53% |
| BeiersdorfBEI | $20.34B | 13.6% | 19.6 | +19.13% |
| EssityESSITY.B | $19.76B | 13.0% | 18.1 | +18.42% |
| UnileverULVR | $142.05B | 20.0% | 13.5 | +19.99% |
| Puig BrandsPUIG | $12.7B | 16.6% | 19.8 | +17.13% |
Same industry or related industries, similar size. Compare Reckitt Benckiser Group with its competitors · Full profile
